Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 4Recruiting 2Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 8Stomach Neoplasms 5Triple Negative Breast Neoplasms 3Liver Neoplasms 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Adrenocortical Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Salivary Gland Neoplasms 1SCLC 1Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Malignant Neoplasms of Digestive Organs 1Locally Advanced Thyroid Gland Carcinoma 1Immunotherapy Gastrict Cancer 1HER2-negative Breast Cancer Brain Metastases 1Gestational Trophoblastic Disease 1

Interventions

Cisplatin 20Radiotherapy 16Paclitaxel 14Carboplatin 12pembrolizumab 11Drug Therapy 11tislelizumab 10Fluorouracil 8Neoadjuvant Therapy 7130-nm albumin-bound paclitaxel 7sintilimab 5Esophagectomy 5toripalimab 4Tegafur 4TP protocol 4Nivolumab 4Irinotecan 4Immunotherapy 4spartalizumab 3S 1 (combination) 3Oxaliplatin 3Leucovorin 3Itraconazole 3Docetaxel 3Albumin-Bound Paclitaxel 3nimotuzumab 2apatinib 2Taxes 2Radiotherapy, Intensity-Modulated 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Esophageal Squamous Cell Carcinoma × apatinib × Clear all
NCT06339619 2026-06-04

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Recruiting
32 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06576973 2025-12-02

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡